购物车
- 全部删除
- 您的购物车当前为空
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA 是 TGF-β 的激活剂。
为众多的药物研发团队赋能,
让新药发现更简单!
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA 是 TGF-β 的激活剂。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 248 | 现货 | |
5 mg | ¥ 502 | 现货 | |
10 mg | ¥ 786 | 现货 | |
25 mg | ¥ 1,430 | 现货 | |
50 mg | ¥ 2,200 | 现货 | |
100 mg | ¥ 3,170 | 现货 | |
200 mg | ¥ 4,470 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 738 | 现货 |
产品描述 | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β . |
体内活性 | LSKL肽的给药减轻了6小时时Smad2的磷酸化。通过LSKL肽,肝细胞的S期进入在24小时和48小时被加速,导致残留肝脏和体重的更快恢复。苏木精-伊红组织染色和血液生化检查显示,两次LSKL肽给药后没有明显的不良影响。在临床环境中,肝切除术后第一天,患者的血浆TSP-1水平最低。然而,在这一阶段,相比术后未出现肝功能障碍的患者,出现后续肝功能障碍的患者血浆TSP-1水平显著较高。 |
动物实验 | Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy. |
别名 | LSKL, Inhibitor of Thrombospondin TSP-1 |
分子量 | 686.64 |
分子式 | C25H44F6N6O9 |
Smiles | CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 27.5 mg/mL (40.05 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容